Innovators in Cancer Immunology: Breast Cancer | Stories | PerkinElmer
Cookies on PerkinElmer
PerkinElmer uses cookies to ensure that we give you the best experience possible on our website. This may include cookies from third party websites. If you continue without changing your settings, we will assume that you consent to receive cookies from this website. You can change your cookie settings at any time. To learn more, please review our cookie policy, which includes information on how to manage your cookies.

Innovators in Cancer Immunology: Breast Cancer

June 09, 2017

Breast Cancer


Elizabeth A. Mittendorf, MD, PhD
Assistant Professor in the Department of Surgical Oncology
University of Texas, MD Anderson Cancer Center, Houston, TX

To advance the understanding of disease mechanisms in cancer, it is critical that researchers see everything a tumor has to show them. Leveraging PerkinElmer’s Phenoptics Quantitative Pathology Research Solutions, researchers are now visualizing and measuring tumor cells and multiple immune-cell phenotypes simultaneously for the first time in formalin-fixed paraffin-embedded (FFPE) tissue.

Because of Phenoptics’ integration of multiplexed immunohistochemistry and imaging, leading scientists are now able to quantitatively capture systems biology data in cellular detail. What follows are brief profiles of some of these Innovators in Cancer Immunology and how they are using Phenoptics to discover new insights into the complexity of immune-cancer interactions that affect countless millions of patients around the world.

Dr. Elizabeth Mittendorf is a breast cancer surgeon who, like most surgeons and oncologists, is making critical decisions every day that impact materially patients’ wellbeing. In her research role, she is looking for better ways to capture tell-tale cancer-immune signatures that will predict how a patient will respond to therapies to help guide her treatment decisions. Today, Dr. Mittendorf is focused on immuno-oncology. Her first study using components of the Phenoptics platform focuses on the role of immune infiltrates in the aggressiveness of Her2+ breast cancer.

Read More Stories Like This One

Tracking Elusive Breast Cancer Cells

New research by PerkinElmer confirms that PD-L1 protein expression levels in human breast cancer cells can be quickly and accurately assessed directly with the A...

Innovators in Cancer Immunology: Lymphoma

Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a lymphoma cancer case study, Dr. Rodig uses t...